Search

Your search keyword '"Hsu, Fred"' showing total 4 results
Start Over Author "Hsu, Fred" Topic quality of life
4 results on '"Hsu, Fred"'

1. Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET

Author

Olson, Robert, Abraham, Hadassah, Leclerc, Curtis, Benny, Alexander, Baker, Sarah, Matthews, Quinn, Chng, Nick, Bergman, Alanah, Mou, Benjamin, Dunne, Emma M., Schellenberg, Devin, Jiang, Will, Chan, Elisa, Atrchian, Siavash, Lefresne, Shilo, Carolan, Hannah, Valev, Boris, Tyldesley, Scott, Bang, Andrew, Berrang, Tanya, Clark, Haley, Hsu, Fred, Louie, Alexander V., Warner, Andrew, Palma, David A., Howell, Doris, Barry, Aisling, Dawson, Laura, Grendarova, Petra, Walker, Debra, Sinha, Rishi, Tsai, Jillian, Bahig, Houda, Thibault, Isabelle, Koul, Rashmi, Senthi, Sashendra, Phillips, Iain, Grose, Derek, Kelly, Paul, Armstrong, John, McDermott, Ronan, Johnstone, Candice, Vasan, Srini, Aherne, Noel, Harrow, Stephen, and Liu, Mitchell

Published
2024
Full Text
View/download PDF

3. Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5.

Author

Olson, Robert, Liu, Mitchell, Bergman, Alanah, Lam, Sonya, Hsu, Fred, Mou, Benjamin, Berrang, Tanya, Mestrovic, Ante, Chng, Nick, Hyde, Derek, Matthews, Quinn, Lund, Chad, Glick, Daniel, Pai, Howard, Basran, Parminder, Carolan, Hannah, Valev, Boris, Lefresene, Shilo, Tyldesley, Scott, and Schellenberg, Devin

Subjects
RADIOTHERAPY, CANCER, METASTASIS, DISEASES, COHORT analysis, CLINICAL trials, COMPARATIVE studies, LONGITUDINAL method, RESEARCH methodology, MEDICAL cooperation, QUALITY of life, RADIOSURGERY, RESEARCH, SURVIVAL analysis (Biometry), EVALUATION research, DISEASE progression
Abstract

Background: Oligometastases refer to a state of disease where cancer has spread beyond the primary site, but is not yet widely metastatic, often defined as 1-3 or 1-5 metastases in number. Stereotactic ablative radiotherapy (SABR) is an emerging radiotherapy technique to treat oligometastases that require further prospective population-based toxicity estimates.Methods: This is a non-randomized phase II trial where all participants will receive experimental SABR treatment to all sites of newly diagnosed or progressing oligometastatic disease. We will accrue 200 patients to assess toxicity associated with this experimental treatment. The study was powered to give a 95% confidence on the risk of late grade 4 toxicity, anticipating a < 5% rate of grade 4 toxicity.Discussion: SABR treatment of oligometastases is occurring off-trial at a high rate, without sufficient evidence of its efficacy or toxicity. This trial will provide necessary toxicity data in a population-based cohort, using standardized doses and organ at risk constraints, while we await data on efficacy from randomized phase III trials.Trial Registration: Registered through clinicaltrials.gov NCT02933242 on October 14, 2016 prospectively before patient accrual. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

4. 31 Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-Based SABR-5 Phase II Trial.

Author

Cruz-Lim, Ella Mae, Mou, Benjamin, Baker, Sarah, Arbour, Gregory, Stefanyk, Kelsey, Jiang, Will, Liu, Mitchell, Bergman, Alanah, Schellenberg, Devin, Alexander, Abraham, Berrang, Tanya, Bang, Andrew, Chng, Nick, Matthews, Quinn, Carolan, Hannah, Hsu, Fred, Miller, Stacy, Atrchian, Siavash, Chan, Elisa, and Ho, Clement

Subjects
*STEREOTACTIC radiotherapy, *QUALITY of life
Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results